24/7 Market News Snapshot 21 April, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)

April 21, 2025

DENVER, Colo., 21 April, 2025 (www.247marketnews.com) – (NASDAQ:RSLS) are discussed in this article.
ReShape Lifesciences, Inc. (NASDAQ:RSLS) is experiencing a notable surge in market activity, currently trading at $0.468 with an impressive increase of over 51% from the previous day’s close of $0.310. During this pre-market session, a remarkable 33.71 million shares have exchanged hands, indicating robust investor interest and enthusiasm surrounding the stock. This momentum is likely driven by recent positive developments that have captured the attention of market participants, suggesting a pivotal moment for the company.

In a significant advancement, ReShape Lifesciences has been granted a Notice of Allowance for its innovative patent application concerning a novel approach to treating Type 2 diabetes and addressing hypoglycemia. This soon-to-be-issued patent, titled “High-Frequency Low Duty Cycle Patterns for Neural Regulation,” highlights the company’s dedication to enhancing patient care through its proprietary vagus nerve modulation technology, known as vBloc™. The patent will secure the technology’s protection until August 4, 2037, thereby facilitating the development of a neuromodulation system designed to improve treatment options for obesity-related diabetes.

This innovative system utilizes approximately ten times less energy than existing devices, enabling smaller batteries and longer intervals between recharges. As Dr. Jonathan Waataja, Director of Research at ReShape Lifesciences®, noted, addressing the global burden of Type 2 diabetes is critical, and the company’s technology aims to optimize insulin production and manage glucose levels effectively.

Paul F. Hickey, President and CEO, further articulated the significance of this patent, emphasizing its role in reinforcing the company’s unique position within the diabetes treatment sector. The Diabetes Neuromodulation technology underscores ReShape’s broader strategy to personalize medical interventions and reduce healthcare costs while augmenting its intellectual property portfolio. With these developments, ReShape Lifesciences is poised to make impactful contributions to the field of metabolic health, advancing its goals for effective commercialization and competitiveness in a rapidly evolving industry.

Related news for (RSLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.